Stay updated on Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Sign up to get notified when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page

  1. Check
    5 days ago
    Change Detected
    Summary
    No substantive changes to core study information were detected; any updates appear to be formatting or metadata adjustments rather than content. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.3%
    Check dated 2025-11-03T01:19:15.000Z thumbnail image
  2. Check
    12 days ago
    No Change Detected
  3. Check
    34 days ago
    Change Detected
    Summary
    Update includes a critical operating status notice and a new software version (v3.2.0), indicating updated deployment with potential service impact; previous version reference (v3.1.0) was removed.
    Difference
    3%
    Check dated 2025-10-05T10:10:45.000Z thumbnail image
  4. Check
    41 days ago
    Change Detected
    Summary
    Update the page version from v3.0.2 to v3.1.0, reflecting a newer release metadata.
    Difference
    0.1%
    Check dated 2025-09-28T03:15:19.000Z thumbnail image
  5. Check
    55 days ago
    Change Detected
    Summary
    Revision updated from v3.0.1 to v3.0.2; 'Back to Top' removed. No changes to pricing, stock, or other core content.
    Difference
    0.2%
    Check dated 2025-09-13T17:35:14.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes in core content, names, pricing, or availability.
    Difference
    0.2%
    Check dated 2025-09-06T14:54:39.000Z thumbnail image
  7. Check
    70 days ago
    Change Detected
    Summary
    The web page has undergone significant updates, including the addition of new facility names and locations in Belgium and France, as well as a range of new medical terms related to proteins and antibodies. Notably, the revision number has been updated to v3.0.0.
    Difference
    4%
    Check dated 2025-08-30T11:44:42.000Z thumbnail image

Stay in the know with updates to Nivolumab in Relapsed/Refractory DLBCL Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab in Relapsed/Refractory DLBCL Clinical Trial page.